Airway-derived emphysema-specific alveolar type II cells exhibit impaired regenerative potential in COPD
Airway-derived emphysema-specific alveolar type II cells zeigen in COPD ein vermindertes Regenerationspotenzial
European Respiratory Journal · 2024-12 · 64 (6) · 2302071
DOI: 10.1183/13993003.02071-2023 ↗Auf einen Blick
Beschrieben wird eine emphysemaspezifische ATII-Zellpopulation in vergrößerten distalen Alveolarsäcken. Humanen und murinen ATII-Subpopulationen bildeten 80–90 % weniger alveoläre Organoide als gesunde Kontrollen.
Fragestellung
Welche Eigenschaften haben emphysemaspezifische ATII-Zellen bei COPD und wie ist ihr Regenerationspotenzial?
Methode
Single-cell-RNA-Sequenzierung und in situ-Lokalisierung; zusätzlich Lineage-Labeling in Maus-COPD-Modellen.
Ergebnisse
asATII-Zellen koexprimierten Surfactant Protein C und SCGB3A2. Humane und murine ATII-Subpopulationen bildeten 80–90 % weniger alveoläre Organoide als gesunde Kontrollen.
Schlussfolgerung der Autor:innen
asATII-Zellen und ihre Vorläufer, die Club-Zellen, könnten neue COPD-Behandlungsstrategien eröffnen.
Kernaussagen
- asATII-Zellen wurden in vergrößerten distalen Alveolarsäcken beschrieben.
- Sie koexprimierten Surfactant Protein C und SCGB3A2.
- Das Organoidwachstum war um 80–90 % reduziert.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 15.08.2024. Verfasst von Yan Hu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Alveolar Epithelial Cells, Regeneration, Pulmonary Emphysema. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, BLRD VA.
Themen: COPD
Abstract (Originalsprache)
Emphysema, the progressive destruction of gas exchange surfaces in the lungs, is a hallmark of COPD that is presently incurable. This therapeutic gap is largely due to a poor understanding of potential drivers of impaired tissue regeneration, such as abnormal lung epithelial progenitor cells, including alveolar type II (ATII) and airway club cells. We discovered an emphysema-specific subpopulation of ATII cells located in enlarged distal alveolar sacs, termed asATII cells. Single-cell RNA sequencing and in situ localisation revealed that asATII cells co-express the alveolar marker surfactant protein C and the club cell marker secretaglobin-3A2 (SCGB3A2). A similar ATII subpopulation derived from club cells was also identified in mouse COPD models using lineage labelling. Human and mouse ATII subpopulations formed 80–90% fewer alveolar organoids than healthy controls, indicating reduced progenitor function. Targeting asATII cells or their progenitor club cells could reveal novel COPD treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
- Center for Lung Aging and Regeneration (CLAR), Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
- Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
- RNA Bioscience Initiative, University of Colorado School of Medicine, Aurora, CO, USA.
- Department of Medicine, National Jewish Health, Denver, CO, USA.
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
ORCID-Profile: Yan Hu, Qianjiang Hu, Ricardo Pineda, Maria C Basil, Mareike Lehmann, Melanie Königshoff
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- BLRD VA
- NIEHS NIH HHS
- NIA NIH HHS
- Chan Zuckerberg Initiative
- German Center for Lung Research (DZL), the Helmholtz Association, the European Union’s Horizon 2020 research and innovation program
- U.S. Department of Veterans Affairs
Zitieren
APA
Hu, Y., Hu, Q., Ansari, M., Riemondy, K., Pineda, R., Sembrat, J., Leme, A. S., Ngo, K., Morgenthaler, O., Ha, K., Gao, B., Janssen, W. J., Basil, M. C., Kliment, C. R., Morrisey, E., Lehmann, M., Evans, C. M., Schiller, H. B., & Königshoff, M. (2024). Airway-derived emphysema-specific alveolar type II cells exhibit impaired regenerative potential in COPD. European Respiratory Journal, 64(6), 2302071. https://doi.org/10.1183/13993003.02071-2023
Vancouver
Hu Y, Hu Q, Ansari M, Riemondy K, Pineda R, Sembrat J, et al. Airway-derived emphysema-specific alveolar type II cells exhibit impaired regenerative potential in COPD. European Respiratory Journal. 2024;64(6):2302071. doi:10.1183/13993003.02071-2023
BibTeX
@article{Hu2024,
author = {Hu, Yan and Hu, Qianjiang and Ansari, Meshal and Riemondy, Kent and Pineda, Ricardo and Sembrat, John and Leme, Adriana S and Ngo, Kenny and Morgenthaler, Olivia and Ha, Kellie and Gao, Bifeng and Janssen, William J and Basil, Maria C and Kliment, Corrine R and Morrisey, Edward and Lehmann, Mareike and Evans, Christopher M and Schiller, Herbert B and Königshoff, Melanie},
title = {Airway-derived emphysema-specific alveolar type II cells exhibit impaired regenerative potential in COPD},
journal = {European Respiratory Journal},
year = {2024},
volume = {64},
number = {6},
pages = {2302071},
doi = {10.1183/13993003.02071-2023}
}
EUVIMED